Skip To Main Content

Inspiration and Innovation

Get inspired and stay on the cutting edge of innovation with these resources.

Sort by

Filters

Reset
  • Therapeutical Areas
  • Type of Content
Odyssey Outcomes - PVD Sub-analysis

Odyssey Outcomes - PVD Sub-analysis

Why compromise for less: Should PCSK9 inhibitors be initial therapy?

Why compromise for less: Should PCSK9 inhibitors be initial therapy?

Odyssey Outcomes - Total Events Analysis

Odyssey Outcomes - Total Events Analysis

Odyssey outcomes - CVOT mortality sub-analysis

Odyssey outcomes - CVOT mortality sub-analysis

LLTs Exposure Time and Major Vascular Risk Reduction

LLTs Exposure Time and Major Vascular Risk Reduction

Improving Lipid Management for Patients Post-ACS

Improving Lipid Management for Patients Post-ACS

Dyslipidemia performance of 2016 2019 and 2021 ESC Dyslipidemia guidelines

Dyslipidemia performance of 2016 2019 and 2021 ESC Dyslipidemia guidelines

The role of the patient in Achieving LDL-C Target

The role of the patient in Achieving LDL-C Target

Identifying and treating patients with high Lipidaemia risk post-ACS

Identifying and treating patients with high Lipidaemia risk post-ACS

Effect of Alirocumab on MACE in patients with CKD

Effect of Alirocumab on MACE in patients with CKD

Lipid management in patients with ACS/ASCVD

Lipid management in patients with ACS/ASCVD

In hospital outcomes in young patients with AMI: Results from Gulf Coast

In hospital outcomes in young patients with AMI: Results from Gulf Coast